AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

CONYGAR INVESTMENT COMPANY PLC (THE)

Regulatory Filings Dec 2, 2022

7574_rns_2022-12-02_1ddcfa26-b33e-4a96-b837-45d8f5b90d5c.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3524I

Conygar Investment Company PLC(The)

02 December 2022

[2nd December 2022]

THE CONYGAR INVESTMENT COMPANY PLC

Planning application for bioscience accommodation

at The Island Quarter, Nottingham

The Conygar Investment Company PLC ("Conygar") has submitted a detailed application for the next phase of The Island Quarter development in Nottingham. The application comprises a 23,123 sq.m. (249,000 sq.ft.) bioscience building, which includes both laboratory and office space.

Christopher Ware, Property Director of Conygar, commented:

"We are delighted to submit this application for the next phase of development. Nottingham is already home to a large number of exciting businesses in the bioscience space and this scheme will be an excellent addition to the mixed-use development we are creating at The Island Quarter".

Enquiries:

The Conygar Investment Company PLC

Christopher Ware: 020 7258 8670 

Liberum Capital Limited (Nominated Adviser and Broker)

Richard Lindley: 020 3100 2185

Temple Bar Advisory (Public Relations)

Alex Child-Villiers: 07795 425580

William Barker: 07827 960151

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFSIFUFEESEEE

Talk to a Data Expert

Have a question? We'll get back to you promptly.